Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 106.99% | 61.62% | -16.30% | -29.38% | -40.77% |
| Total Depreciation and Amortization | -10.47% | 25.92% | 22.38% | 24.55% | 21.58% |
| Total Amortization of Deferred Charges | 119.15% | 520.64% | -- | -- | -- |
| Total Other Non-Cash Items | -193.30% | -172.70% | -173.84% | 57.42% | 125.70% |
| Change in Net Operating Assets | -103.06% | 115.26% | 481.91% | 440.32% | 1,079.50% |
| Cash from Operations | 105.77% | 85.98% | 16.05% | 12.05% | 7.61% |
| Capital Expenditure | 77.63% | 58.51% | 46.28% | -150.00% | -146.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 52.51% | 42.17% | 12.01% | -7.56% | -15.28% |
| Cash from Investing | 56.73% | 44.74% | 18.05% | -18.49% | -26.38% |
| Total Debt Issued | -88.00% | -13.33% | -- | -- | -- |
| Total Debt Repaid | -36.04% | -36.04% | 40.97% | -5.37% | -27.98% |
| Issuance of Common Stock | 29,163.64% | 29,163.64% | -100.00% | -100.00% | -91.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -82.18% | 229.44% | 36.94% | -51.33% | -56.86% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 90.83% | -7,112.33% | -1,898.03% | -1,347.14% | -1,291.04% |
| Cash from Financing | -83.35% | 137.59% | 91.52% | -41.02% | -48.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 159.92% | 185.70% | 81.19% | -243.23% | -174.58% |
